Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01679197
Other study ID # MCRU 2834
Secondary ID R01DK088114-02
Status Completed
Phase Phase 2
First received August 31, 2012
Last updated February 3, 2017
Start date October 8, 2012
Est. completion date July 13, 2016

Study information

Verified date February 2017
Source University of Michigan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study involves research about an investigational medicine called metreleptin. The reason for this study is to find out how metreleptin can improve non-alcoholic steatohepatitis or nonalcoholic fatty liver disease associated with lipodystrophy, a rare disorder associated with abnormal loss of the body's fat tissue. In this study, metreleptin is considered to be investigational for the treatment of lipodystrophy. Metreleptin will be given via injections under the skin. We plan to continue therapy for a period of one year and evaluate the change in liver disease by a liver biopsy. We will also follow the metabolic parameters (e.g. blood cholesterol, liver function, insulin resistance) and body composition characteristics (e.g. the pattern of fat distribution in the body).


Description:

The goal is to test the efficacy of restorative leptin therapy on the degree of hepatic steatosis and on amelioration of pathological features of NASH/NAFLD. In addition, the study will evaluate the impact of leptin therapy on total body insulin sensitivity and lipid levels as well as energy expenditure. In order to accomplish this aim, we now propose an efficacy study with recombinant human leptin therapy in patients with all forms of lipodystrophy who also have NASH/NAFLD.

1. AIM 1: To determine the efficacy of leptin in promoting amelioration of body composition, hepatic steatosis and histopathological scores in patients with all forms of lipodystrophy and NAFLD/NASH. We will conduct a 1 year, open-label study, to assess the metabolic effects of recombinant human leptin (METRELEPTIN, AztraZeneca, Wilmington, DE). The primary outcome measure will be NASH scores. We will also explore body weight, insulin sensitivity, glucose and lipid control, body composition, and free fatty acid levels.

2. AIM 2: To Investigate molecular effects of leptin therapy. In parallel to our preliminary studies, gene expression will be performed on individuals participating in Aim 1 at baseline and following 1 year of leptin. We will combine this with measures of liver metabolite levels to provide novel insights into alterations in metabolism that occur secondary to leptin therapy. We will also measure plasma metabolites at baseline and after 2 (optional), 24 and 48 weeks of therapy to assess the dynamic changes induced by leptin and correlate these changes with phenotypic measures.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date July 13, 2016
Est. primary completion date July 13, 2016
Accepts healthy volunteers No
Gender All
Age group 5 Years and older
Eligibility Inclusion Criteria:

- Is male or female = 5 years old at baseline.

- Is male, female not of childbearing potential, or meets all the following criteria if female of childbearing potential (including perimenopausal women who have had a menstrual period within one year):

- Not breastfeeding

- Negative pregnancy test result (human chorionic gonadotropin, beta subunit [ßhCG]) at baseline (not applicable to hysterectomized females).

- Must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate when use consistently and correctly, such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire duration of metreleptin treatment.

- Has physician-confirmed lipodystrophy as defined by evidence of generalized (whole body) or partial (limbs) loss of body fat outside the range of normal variation.

- Alcohol consumption of less than 40 grams/week.

- A liver ultrasound confirming non-alcoholic fatty liver disease, or previous liver biopsy confirming NASH status.

- If = 18 years of age, is able to read, understand and sign the U of M IRBMED approved informed consent form (ICF), communicate with study physician and study team, understand and comply with protocol requirements.

- If < 18 and = 7 years of age, is able to read, understand and sign the appropriate U of M IRBMED approved assent form and has a parent or legal guardian that is able to read, understand and sign the ICF.

- If < 7 and = 5 years of age or unable to read, the appropriate assent form must be explained to the child.

- If previously treated with thiazolidinediones or Vitamin E, stable dose of these medications for at least 3 months.

Exclusion Criteria:

- Presence of advanced liver disease (as evidenced by abnormal synthetic function, abnormal PT or albumin).

- Evidence of other etiologies of viral hepatitis.

- Presence of clinically significant hematologic abnormalities (such as neutropenia and/or lymphadenopathy).

- Presence of HIV infection.

- Very poorly controlled diabetes; HbA1c >10%

- Inability to give informed consent.

- Presence of ESRD, any type of active cancer, or >class 2 congestive heart failure ((New York Heart Association Functional Classification System), based on medical history and physical examination.

- Active infection (may be transient).

- Has known allergies to E. coli-derived proteins or hypersensitivity to any component of metreleptin treatment.

- Any other condition in the opinion of the investigators that may impede successful data collection.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Metreleptin


Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (2)

Lead Sponsor Collaborator
University of Michigan National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Liver histopathology Primary outcome will be the Total NASH score read histopathologically from the liver biopsy samples, as determined by the NIH NASH Clinical Network criteria. At baseline and at the end of the year, patients will undergo a transcutaneous liver biopsy and the specimen will be graded for the severity of NAFLD/NASH pathology. 1 year
Secondary Liver fat by MRI and MR spectroscopy All enrolled patients will have a baseline MRI of the liver to evaluate liver volume and liver fat. For determination of hepatic fat content by MRI and MR spectroscopy in patients, a series of out-phase and in-phase MRI at multiple flip angles are used. By combination of out-phase and in-phase MRI at multiple flip-angles and TE times, relaxation-time effects can be removed to yield quantitative intra-hepatic (and other organs') fractional fat content throughout the liver in a few breath-hold intervals. 1 year
Secondary Liver function tests 1 year
Secondary Fasting lipids 1 year
Secondary Fasting glucose 1 year
Secondary Body weight 1 year
See also
  Status Clinical Trial Phase
Completed NCT03375008 - Predictable MR Index for Nonalcoholic Steatohepatitis (NASH) N/A
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Completed NCT02654977 - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Phase 2
Recruiting NCT05211284 - Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US Phase 2
Completed NCT02421094 - Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis Phase 2
Completed NCT01205087 - Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody (mAb)in Patients With the Metabolic Syndrome Phase 2
Recruiting NCT00152711 - Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis N/A
Completed NCT02217475 - Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Phase 2
Completed NCT04031729 - Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease Phase 1/Phase 2
Completed NCT03674476 - An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function Phase 1
Recruiting NCT03725631 - Non-invasive Evaluation of Liver Fibrosis, Steatosis, and NASH in NAFLD N/A
Terminated NCT04565717 - A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) Phase 1
Active, not recruiting NCT05084404 - Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease Phase 2
Active, not recruiting NCT02574325 - A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis Phase 2
Terminated NCT00878592 - Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity N/A
Recruiting NCT02148471 - Fatty Acids, Genes and Microbiota in Fatty Liver N/A
Completed NCT00227110 - Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Phase 4
Completed NCT03656744 - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Phase 2
Completed NCT03068078 - A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes N/A